SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (Date of earliest event reported): September 26,
2016
Echo Therapeutics, Inc.
(Exact name of Company as specified in its
charter)
|
|
|
|
|
|
|
Delaware
|
|
001-35218
|
|
41-1649949
|
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
99
Wood Avenue South., Suite 302
Iselin, NJ
|
08830
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Company’s telephone number, including area code: (732)
201-4194
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Company under
any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
5.02
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers: Compensatory Arrangements of
Certain Officers
Effective as of
September 26, 2016, Dr. Elazer Edelman resigned as a member of the
board of directors of Echo Therapeutics, Inc. (the
“Company”) and from the Company’s audit
committee. Dr. Edelman’s resignation was not the result of
any dispute or disagreement with the Company or the Company’s
board of directors on any matter relating to the operations,
policies or practices of the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
ECHO THERAPEUTICS, INC.
|
|
|
Dated:
September 27, 2016
|
By:
/s/ Alan W.
Schoenbart
|
|
|
|
Alan W.
Schoenbart
|
|
|
|
Chief
Financial Officer
|
|
|
|
|
|